Publications by authors named "Dinesh Parshuram Satpute"
Article Synopsis
- The text discusses a new method for activating distal C-H bonds to create benzofulvenes, which are compounds formed through a [3 + 2] reaction involving palladium catalysis, overcoming traditional bond activation challenges.
- This innovative approach involves concurrent activation of both β-C(benzylic)-H and δ-C(aryl)-H bonds and leads to the formation of novel chemical entities with promising anticancer properties.
- In studies, these new compounds were found to effectively target oral squamous cell carcinoma (OSCC) by arresting the cell cycle at the S-phase and activating various apoptosis pathways, indicating their potential as effective chemotherapy options.
Oral squamous cell carcinoma (OSCC) is the most common malignant epithelial neoplasm, affects the mouth and throat, and accounts for 90 % of oral cancers. Considering the associated morbidity with neck dissections and the limitation of existing therapeutic agents, the discovery and development of new anticancer drugs/drug candidates for oral cancer treatment are of the utmost need. In this context, reported here is the identification of fluorinated 2‑styryl 4(3H)-quinazolinone as a promising hit for oral cancer.
View Article and Find Full Text PDFMale breast cancer (MBC) is a relatively rare disease, but emerging data recommend the development of novel therapeutics considering its alarming threats. Compared to female breast cancer (FBC), MBC is reportedly associated with inferior outcomes (poor survival) owing to their late diagnosis and lack of adequate treatment. Treatment typically correlates with FBC, involving surgical removal of the breast tissue along with chemo/hormonal/radiation therapy, the tamoxifen being a standard adjuvant.
View Article and Find Full Text PDF'Epigenetic' regulation of genes via post-translational modulation of proteins is the current mainstay approach for the disease therapies, particularly explored in the Histone Deacetylase (HDAC) class of enzymes. Mainly sight saw in cancer chemotherapeutics, HDAC inhibitors have also found a promising role in other diseases (neurodegenerative disorders, cardiovascular diseases, and viral infections) and successfully entered in various combination therapies (pre-clinical/clinical stages). The prevalent flexibility in the structural design of HDAC inhibitors makes them easily tuneable to merge with other pharmacophore modules for generating multi-targeted single hybrids as a novel tactic to overcome drawbacks of polypharmacy.
View Article and Find Full Text PDF